A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes
| Status: | Completed |
|---|---|
| Conditions: | High Cholesterol, Diabetes |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 3/31/2019 |
| Start Date: | April 2012 |
| End Date: | October 2012 |
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes
This Phase 2 study will asses the LDL-C lowering efficacy of ETC-1002 versus placebo in
subjects with type 2 diabetes.
subjects with type 2 diabetes.
Inclusion Criteria:
- Diagnosis of type 2 diabetes meeting all of the following:
- Minimum 6 month history of diabetes prior to screening visit;
- Fasting C-peptide ≥ 0.8 ng/mL at screening visit;
- HbA1C at screening visit 7-10%;
- Fasting glucose from 140-270 mg/dL on Day -7 following washout of all glucose
regulating drugs and supplements.
- BMI at screening visit from 25-35 kg/m2;
- LDL-C at screening ≥ 100 mg/dL
We found this trial at
1
site
Click here to add this to my saved trials
